Prestige Biologics Co Ltd
334970
Company Profile
Business description
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
Contact
197, Osongsaengmyeong 1-ro
Osong-eup, Heungdeok-gu
Chungcheongbuk-do
Cheongju-si28161
KORT: +82 432321552
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
293
Stocks News & Analysis
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
stocks
After earnings, we raise our Tesla stock Fair Value Estimate. Are shares a buy?
Solid results included strong full-self driving software uptake and positive free cash flow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,736.85 | 26.68 | 0.19% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |